Asarina Pharma Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • PIPE

  • Latest Deal Amount
  • $4.9M

  • Investors
  • 6

Asarina Pharma General Information

Description

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Contact Information

Formerly Known As
Umecrine Mood
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Karolinska Institutet Science Park
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden
+46 08-524
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Karolinska Institutet Science Park
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden
+46 08-524

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asarina Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. PIPE 24-Oct-2019 $4.9M Completed Generating Revenue
6. Secondary Transaction - Private 24-Oct-2019 Completed Generating Revenue
5. IPO 24-Sep-2018 Completed Generating Revenue
4. Later Stage VC 07-Nov-2016 Completed Generating Revenue
3. Later Stage VC 30-Apr-2014 Completed Generating Revenue
2. Early Stage VC 13-Apr-2011 $5.66M $5.66M Completed Startup
1. Early Stage VC Completed Startup
To view Asarina Pharma’s complete valuation and funding history, request access »

Asarina Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 329,170 $6.74 $6.74 1x $6.74 18.47%
Ordinary 267,500 $6.74 $6.74 1x $6.74 15.01%
To view Asarina Pharma’s complete cap table history, request access »

Asarina Pharma Patents

Asarina Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020011789-A1 Injectable suspensions Inactive 09-Jul-2018
AU-2019249932-A1 Gaba-a antagonists for treating substance withdrawal disorders Inactive 05-Apr-2018
CA-3094026-A1 Gaba-a antagonists for treating substance withdrawal disorders Inactive 05-Apr-2018
EP-3773599-A1 Gaba-a antagonists for treating substance withdrawal disorders Inactive 05-Apr-2018
US-20210161915-A1 Gaba-a antagonists for treating substance withdrawal disorders Inactive 05-Apr-2018 A61K31/57
To view Asarina Pharma’s complete patent history, request access »

Asarina Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asarina Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fjärde AP-fonden Limited Partner Minority
Svenska Handelsbanken Corporation Minority
Swedbank Robur Asset Manager Minority
Ergomed Group PE-Backed Company Minority
Rosetta Capital (UK) Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Asarina Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Asarina Pharma’s complete esg history, request access »

Asarina Pharma FAQs

  • When was Asarina Pharma founded?

    Asarina Pharma was founded in 2006.

  • Where is Asarina Pharma headquartered?

    Asarina Pharma is headquartered in Solna, Sweden.

  • What is the size of Asarina Pharma?

    Asarina Pharma has 7 total employees.

  • What industry is Asarina Pharma in?

    Asarina Pharma’s primary industry is Drug Discovery.

  • Is Asarina Pharma a private or public company?

    Asarina Pharma is a Private company.

  • What is Asarina Pharma’s current revenue?

    The current revenue for Asarina Pharma is .

  • How much funding has Asarina Pharma raised over time?

    Asarina Pharma has raised $36.5M.

  • Who are Asarina Pharma’s investors?

    Fjärde AP-fonden, Svenska Handelsbanken, Swedbank Robur, Ergomed Group, and Rosetta Capital (UK) are 5 of 6 investors who have invested in Asarina Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process